RxDoctor Payments Data

Giora Weisz, MD

Interventional Cardiology · New York, NYNPI 1306891767

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $69,707 of the $88,205 with a category attached, or 79.0%. 24 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 46.6% of the total. Reporting peaked in 2020 at $42,467 and has fallen 98.9% since, to $468 in 2025.

$88,205in general payments, 2019–2025

Across 132 payments — averaging $668.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$41K
  • Corindus Inc.$20K
  • Philips North America LLC$6K
  • Boston Scientific$6K
  • Magenta Medical Inc$5K
  • Cardiovascular Systems Inc.$3K
  • plus $7K from 18 others
$818,949in research payments, 2019–2025

Across 96 payments — averaging $8530.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cardiovascular Systems Inc.$378K
  • Abbott$352K
  • Shockwave Medical, Inc$89K

What the payments were for

  • Consulting fees$69,70779%
  • Speaking & faculty fees$1,6202%
  • Travel & lodging$9,63811%
  • Food & beverage$7,2228%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$88,205 in reported general payments places this provider in the 85th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$36,268
Medicare patients
54
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rosuvastatin Calcium20$433
Ezetimibe14$345

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →